The SELECT trial enrolled 17,604 patients with a mean body mass index (BMI) of 33.3 and preexisting cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) but no diabetes
Discontinuing peptide therapy often leads to weight regain
Semaglutide and tirzepatidethe active compoundsare FDA-approved for weight loss and diabetes
This approach maintains therapeutic effect and minimizes any potential weight regain during transition
Starting at $200 A month, our Weight Loss Program Includes: An initial in office or Telehealth consultation with one of our medical doctors (MDs) is required to determine if Semaglutide or Tirzepatide is right for you based on your BMI and medical and history
TB-500, a synthetic fragment corresponding to the active region of the endogenous peptide Thymosin Beta-4, drives the cellular migration phase of repair by sequestering G-actin, promoting cell motility, and mobilising stem and progenitor cells to sites of tissue disruption